Exponent (EXPO) CEO option exercise and sale leaves 84,134 shares held

Q: What insider transaction did Exponent (EXPO) report in this Form 4?

Exponent reported that Catherine Corrigan , its President & CEO and a director, exercised a stock option for 3,225 shares and sold 3,225 shares of common stock on 12/15/2025 .

Q: How many Exponent (EXPO) shares did the CEO sell and at what price?

Catherine Corrigan sold 3,225 shares of Exponent common stock at a price of $70.7387 per share.

Q: How many Exponent (EXPO) stock options does the CEO still hold?

After the transaction, Catherine Corrigan held 16,128 non-qualified stock options, each relating to Exponent common stock.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Exponent Inc. President & CEO and director Catherine Corrigan reported an insider stock transaction. On 12/15/2025, she exercised a non-qualified stock option for 3,225 shares of common stock at an exercise price of $25.405 per share, increasing her directly held shares. On the same day, she sold 3,225 shares of common stock at a price of $70.7387 per share. After these transactions, she directly owned 84,134 shares of Exponent common stock and held 16,128 non-qualified stock options.

Insider Trade Summary

Net Seller: 3,225 shares ($228,132)

Net Sell 3 txns

Insider Corrigan Catherine

Role President & CEO

Sold 3,225 shs ($228K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	3,225	$0.00	--
Exercise	Common Stock	3,225	$25.405	$82K
Sale	Common Stock	3,225	$70.7387	$228K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 16,128 shares (Direct); Common Stock — 87,359 shares (Direct)

Footnotes (1)

The stock option becomes exercisable in four equal annual installments. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

12/16/2025 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corrigan Catherine

(Last)

(First)

(Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/15/2025		M		3,225	A	$25.405	87,359	D
Common Stock	12/15/2025		S		3,225	D	$70.7387	84,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$25.405	12/15/2025		M			3,225	⁽¹⁾	07/29/2026	Common Stock	3,225	⁽²⁾	16,128	D

Explanation of Responses:

1. The stock option becomes exercisable in four equal annual installments.

2. Not applicable.

	By: Wendy Whitehouse For: Catherine Corrigan	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Exponent (EXPO) report in this Form 4?

Exponent reported that Catherine Corrigan, its President & CEO and a director, exercised a stock option for 3,225 shares and sold 3,225 shares of common stock on 12/15/2025.

How many Exponent (EXPO) shares did the CEO sell and at what price?

Catherine Corrigan sold 3,225 shares of Exponent common stock at a price of $70.7387 per share.

What was the exercise price of the Exponent (EXPO) stock option?

The non-qualified stock option was exercised at an exercise price of $25.405 per share for 3,225 shares of Exponent common stock.

How many Exponent (EXPO) shares does the CEO own after the transaction?

Following the reported transactions, Catherine Corrigan directly owned 84,134 shares of Exponent common stock.

How many Exponent (EXPO) stock options does the CEO still hold?

After the transaction, Catherine Corrigan held 16,128 non-qualified stock options, each relating to Exponent common stock.

When do the reported Exponent (EXPO) stock options expire?

The reported non-qualified stock option has an expiration date of 07/29/2026, and it becomes exercisable in four equal annual installments.